Ashwani Verma
Stock Analyst at UBS
(4.09)
# 569
Out of 5,055 analysts
95
Total ratings
62.32%
Success rate
9.76%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Neutral | $195 → $220 | $235.51 | -6.59% | 1 | Nov 7, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $580 → $600 | $478.50 | +25.39% | 10 | Nov 6, 2025 | |
| EXEL Exelixis | Maintains: Neutral | $35 → $40 | $42.50 | -5.88% | 5 | Nov 6, 2025 | |
| AVDL Avadel Pharmaceuticals | Downgrades: Neutral | $20 | $23.09 | -13.38% | 4 | Oct 28, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $50 → $43 | $33.97 | +26.58% | 3 | Oct 15, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $188 → $195 | $138.98 | +40.31% | 10 | Oct 9, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $23 → $26 | $24.93 | +4.29% | 10 | Sep 24, 2025 | |
| BHVN Biohaven | Maintains: Buy | $27 → $26 | $9.60 | +170.83% | 4 | Sep 16, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $36 → $39 | $23.60 | +65.25% | 8 | Sep 9, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $133 → $144 | $148.42 | -2.98% | 5 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $18 | $23.61 | -23.76% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $54 | $29.70 | +81.82% | 3 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $33 → $42 | $29.18 | +43.93% | 5 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $61 | $104.73 | -41.75% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $47 → $41 | $67.31 | -39.09% | 5 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $1.05 | $1.23 | -14.29% | 5 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $145 → $179 | $180.87 | -1.03% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $114 | $90.31 | +26.23% | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $39.40 | -28.93% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $137.81 | -94.92% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $10.83 | +10.80% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $1.89 | +693.65% | 1 | Oct 11, 2022 |
AbbVie
Nov 7, 2025
Maintains: Neutral
Price Target: $195 → $220
Current: $235.51
Upside: -6.59%
United Therapeutics
Nov 6, 2025
Maintains: Buy
Price Target: $580 → $600
Current: $478.50
Upside: +25.39%
Exelixis
Nov 6, 2025
Maintains: Neutral
Price Target: $35 → $40
Current: $42.50
Upside: -5.88%
Avadel Pharmaceuticals
Oct 28, 2025
Downgrades: Neutral
Price Target: $20
Current: $23.09
Upside: -13.38%
Harmony Biosciences Holdings
Oct 15, 2025
Maintains: Buy
Price Target: $50 → $43
Current: $33.97
Upside: +26.58%
Neurocrine Biosciences
Oct 9, 2025
Maintains: Buy
Price Target: $188 → $195
Current: $138.98
Upside: +40.31%
Teva Pharmaceutical Industries
Sep 24, 2025
Maintains: Buy
Price Target: $23 → $26
Current: $24.93
Upside: +4.29%
Biohaven
Sep 16, 2025
Maintains: Buy
Price Target: $27 → $26
Current: $9.60
Upside: +170.83%
ACADIA Pharmaceuticals
Sep 9, 2025
Maintains: Buy
Price Target: $36 → $39
Current: $23.60
Upside: +65.25%
Axsome Therapeutics
Aug 6, 2025
Maintains: Buy
Price Target: $133 → $144
Current: $148.42
Upside: -2.98%
Jul 28, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $23.61
Upside: -23.76%
Jul 2, 2025
Maintains: Buy
Price Target: $60 → $54
Current: $29.70
Upside: +81.82%
Jun 17, 2025
Upgrades: Buy
Price Target: $33 → $42
Current: $29.18
Upside: +43.93%
Jun 3, 2025
Maintains: Neutral
Price Target: $61
Current: $104.73
Upside: -41.75%
May 2, 2025
Maintains: Neutral
Price Target: $47 → $41
Current: $67.31
Upside: -39.09%
Apr 24, 2025
Maintains: Neutral
Price Target: $1.5 → $1.05
Current: $1.23
Upside: -14.29%
Mar 7, 2025
Upgrades: Buy
Price Target: $145 → $179
Current: $180.87
Upside: -1.03%
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $90.31
Upside: +26.23%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $39.40
Upside: -28.93%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $137.81
Upside: -94.92%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $10.83
Upside: +10.80%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $1.89
Upside: +693.65%